Corneal Cross-Linking (CXL)

Corneal cross-linking (CXL) is a stabilizing procedure rather than a vision-correction procedure. Riboflavin and UV-A light are used to create new chemical bonds between corneal collagen fibers, making the cornea stiffer. It was the first treatment shown to slow or halt progression of keratoconus, where the cornea thins and bulges forward into a cone shape. The same principle is used for post-LASIK ectasia and related corneal-weakening disorders. CXL usually does not reverse existing shape change; its main role is to prevent further progression.

What CXL Treats

Keratoconus

The leading indication. Keratoconus typically develops in the teenage years or early twenties, with progressive corneal thinning and steepening that distorts vision. Without treatment, a substantial fraction of patients eventually need rigid contact lenses, scleral lenses, or corneal transplantation. CXL is now offered to most patients with documented progression - usually at the time of diagnosis if the patient is young, or whenever progression is shown on serial corneal topography.

Post-Refractive-Surgery Ectasia

After LASIK, PRK, or other refractive procedures, a small minority of corneas progressively weaken and thin, producing a similar shape change to keratoconus. CXL is the standard treatment.

Pellucid Marginal Degeneration

A related corneal-thinning disorder in which the inferior cornea thins peripherally. CXL can stabilize the cornea, although the response varies.

Severe Refractory Keratitis (Off-Label / Investigational)

Some studies have used CXL with riboflavin and UV-A for severe bacterial or fungal corneal infections that have not responded to medical therapy. Evidence is evolving and use varies by center.

When CXL Is Not Indicated

• Stable, non-progressive keratoconus or ectasia (no clear evidence that CXL benefits a stable cornea)
• Cornea too thin to safely undergo treatment (typically less than 400 microns at the thinnest point after epithelial removal; the epithelium is roughly 50-60 microns thick, so a pre-op pachymetry around 450-460 microns is the practical floor - specialized protocols using hypotonic riboflavin or contact-lens-assisted CXL can accommodate thinner corneas in selected cases)
• Significant active corneal scarring or infection at the time of treatment

How It Works

The cornea is built largely of collagen fibers organized in tightly woven layers. In keratoconus and related disorders, the natural cross-links between these fibers weaken, allowing the cornea to deform and thin under normal eye pressure.

CXL adds new bonds. The simplified version:

1. Riboflavin (vitamin B2) drops are applied to the cornea over 20-30 minutes. Riboflavin diffuses into the corneal stroma and acts as a photosensitizer.
2. Ultraviolet-A (UV-A) light at 365 nm is then applied to the cornea for 3-30 minutes (varying by protocol)
3. The combination of riboflavin and UV-A generates reactive oxygen species that create new chemical bonds - cross-links - between collagen fibers
4. The newly cross-linked cornea is significantly stiffer, and disease progression often stabilizes

The Dresden protocol delivers UV-A at 3 mW/cm² for 30 minutes, for a total dose of 5.4 J/cm². Modern accelerated protocols use higher intensity for shorter times (e.g., 9 mW/cm² for 10 minutes, or 18 mW/cm² for 5 minutes), targeting the same total UV-A energy delivered to the cornea. In the United States, the FDA-approved epi-off CXL system is iLink (Glaukos/Avedro) - using Photrexa Viscous and Photrexa riboflavin formulations with the KXL UV-A device - approved April 15, 2016 for progressive keratoconus and corneal ectasia after refractive surgery. FDA-approved epi-on protocols now also exist for selected keratoconus patients using dedicated drug/device combinations, including EPIOXA with the O2n System for keratoconus patients 13 years and older; other devices and non-approved accelerated or epi-on protocols remain off-label or investigational in the U.S.

Epi-Off vs. Epi-On

The corneal epithelium - the outermost layer - is a barrier to riboflavin penetration. Two main approaches exist:

Epi-Off (Long-Established Standard)

The epithelium is gently scraped off before riboflavin is applied. Riboflavin penetrates well, UV-A treatment is highly effective, and outcomes are well established. The downside is several days of significant eye discomfort, blurred vision, and the standard healing of an epithelial defect (much like recovery from PRK).

Epi-On

The epithelium is left intact, with specific techniques used to allow riboflavin to penetrate. Historically, epi-on results were less consistent than epi-off, but FDA-approved epithelium-on cross-linking protocols are now available for keratoconus using dedicated riboflavin formulations and device systems.

The choice depends on patient factors, surgeon experience, disease stage, and available protocol equipment. Epi-off has the longest track record; epi-on may offer a faster, more comfortable recovery in selected patients.

What to Expect

Before the Procedure

• A complete corneal evaluation including corneal topography, pachymetry (corneal thickness), and slit lamp examination
• Documentation of progression - at least one prior topography showing the cornea has worsened, or strong clinical reasons to act preemptively
• Discussion of expected outcome (stabilization rather than vision improvement)
• Stop contact lens wear typically 1-2 weeks before the procedure (longer for rigid lenses) so the cornea returns to its baseline shape
• No special preparation on the day of the procedure beyond avoiding eye makeup

During the Procedure

• The patient lies down on a special bed
• Topical anesthetic drops eliminate pain
• The eyelid is held open with a small speculum
• For epi-off procedures: the central corneal epithelium is removed (about 8-9 mm circular area)
• Riboflavin drops are applied for 20-30 minutes
• UV-A light is applied for 3-30 minutes depending on protocol, usually with intermittent breaks for additional riboflavin
• Total procedure time is typically 30-90 minutes per eye
• Both eyes are usually treated separately, days to weeks apart

Recovery (Epi-Off)

• A bandage contact lens is placed at the end of the procedure to help epithelial healing
• The eye will feel uncomfortable to painful for 3-5 days - gritty, light-sensitive, watery
• Vision is blurred for the first week or two, then gradually improves
• Antibiotic and steroid drops are prescribed for several weeks
• The bandage contact lens is removed at 5-7 days when the epithelium has healed
• Vision continues to improve over weeks; the corneal shape may continue to change subtly for 6-12 months

Recovery (Epi-On)

Often faster and more comfortable than epi-off recovery. Many patients can return to normal activities within 1-2 days, with substantially less pain and less blur.

Outcomes

The classic measure of CXL success is stabilization - no further progression of the corneal shape over time. Studies consistently show:

• More than 90% of corneas remain stable in many 5-year series following standard epi-off CXL
• A subset of corneas show some flattening of the cone over time (often described as 1-2 diopters of reduction in maximum corneal steepness)
• A minority of patients have minor improvement in best-corrected vision
• Patients who continue to progress despite CXL are uncommon; some centers offer repeat treatment in selected cases

CXL is not a vision-correction procedure. Many patients still benefit from glasses, soft contact lenses, rigid gas-permeable lenses, or scleral lenses for visual rehabilitation after the cornea has been stabilized.

Risks

CXL has a strong safety record. Possible complications, mostly uncommon and usually manageable:

• Pain and discomfort during epithelial healing (epi-off) - universal but transient
• Corneal haze - a mild diffuse haze develops in roughly half of patients during healing; usually fades over months. Persistent dense haze occurs in a small minority.
• Corneal infection - rare but serious; risk in the days to weeks after treatment while the epithelium heals. Adherence to drops and contact lens hygiene is essential.
• Sterile infiltrates - small focal opacities that resolve with steroid drops
• Persistent epithelial defect - slow healing, usually managed with bandage contact lens, lubrication, and rarely amniotic membrane
• Corneal endothelial damage - very rare. UV-A above the safe threshold can damage the endothelial cell layer at the back of the cornea; the 400-micron minimum stromal-thickness criterion exists to keep UV-A energy at the endothelium below this toxicity threshold
• Failure of stabilization - uncommon; some patients continue to progress despite treatment

Who Is a Candidate

The strongest candidates are:

• Patients with documented progression of keratoconus or post-refractive-surgery ectasia
• Younger patients (teens, twenties) - who are most at risk for further progression
• Adequate corneal thickness (typically at least 400 microns at the thinnest point after epithelial removal for standard epi-off protocols)
• No active corneal infection or significant scarring at the planned treatment site

Patients with stable disease for many years on serial topography may be observed rather than treated. The decision is individualized, weighing rate of progression, age, baseline vision, and other factors.

Frequently Asked Questions

Will my vision get better after CXL?

For most patients, no. CXL is a stabilizing treatment - its goal is to prevent further worsening of the cornea. Some patients have mild flattening of the cone and a small improvement in best-corrected vision, but the typical outcome is stable vision rather than improved vision. Visual rehabilitation after CXL often involves glasses, contact lenses, or scleral lenses.

Why does the procedure hurt for several days?

The standard epi-off protocol removes the corneal epithelium, the outermost cell layer, so riboflavin can penetrate. That leaves an open surface wound on the cornea. The first few days can be painful, similar to PRK or a deep corneal abrasion. Pain medication, lubrication, and a bandage contact lens help manage symptoms while the surface heals.

Can both eyes be done at the same time?

Most surgeons treat one eye at a time, separated by days to weeks, so that the patient is not without functional vision during the most uncomfortable part of recovery. Some centers offer same-day bilateral CXL in selected cases.

Will I still need contact lenses or glasses after CXL?

Almost certainly. CXL stabilizes the cornea but does not restore its original shape. Whatever your prescription needs were before the procedure, you will need similar correction after, although your contact lens fit may need to be adjusted as the cornea settles into its new stable form.

How do I know whether my keratoconus is progressing and whether I need this?

Progression is determined by repeat corneal topography over months to years. An increase in maximum corneal steepness (Kmax) of 1 diopter or more, a decrease in central corneal thickness, or a change in the shape pattern that the doctor identifies on serial scans usually indicates progression and supports CXL.

What happens if I don't have CXL?

Some patients with mild, stable keratoconus do well long-term with glasses or specialty contact lenses. Patients with active progression risk reaching a point where contact lenses no longer correct vision, where scarring develops, or where corneal transplantation becomes necessary. CXL was developed precisely to interrupt this progression before it gets there, and its long-term outcomes have substantially changed the natural history of keratoconus over the last 15 years.

References